Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

20
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
20
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

17
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
17
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

10
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Performance of common fetal growth standards in pregnancies affected by systemic lupus erythematosus.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

Another step toward phenotypic characterization of hereditary dysfibrinogenemia?

Research and practice in thrombosis and haemostasis·2026
Same author

IgM antiphospholipid antibodies are associated with a microvascular phenotype in antiphospholipid syndrome.

Advances in rheumatology (London, England)·2026
Same author

Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation.

Lupus science & medicine·2026
Same author

"More guidelines than rules": reconsidering key gaps in the 2025 American College of Rheumatology treatment recommendations for systemic lupus erythematosus: comment on the article by Sammaritano et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

DNA (cytosine-5)-methyltransferase 3A (Dnmt3a) mutations limit normal and autoreactive CD4+ T follicular helper responses and attenuate T cell-driven joint inflammation.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Treatment of Patients with CPPD Disease: Where Do We Begin and Where Are We Going?

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Fibroblast Mitochondrial Ca2+ Overload Drives Skin Fibrosis via mtDNA Leakage and cGAS-STING Activation in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients with Rheumatoid Arthritis: Response to Gao et al.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same journal

Diagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral Spondyloarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Jul 18, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

2.4K

The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

Medha Barbhaiya1, Stephane Zuily2, Ray Naden3

  • 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.

Arthritis & Rheumatology (Hoboken, N.J.)
|August 28, 2023
PubMed
Summary
This summary is machine-generated.

New antiphospholipid syndrome (APS) classification criteria offer high specificity for research. Developed by ACR/EULAR, these criteria improve APS diagnosis in observational studies and trials.

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.9K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

428

Related Experiment Videos

Last Updated: Jul 18, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

2.4K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.9K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

428

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Criteria Development

Background:

  • Antiphospholipid syndrome (APS) requires precise classification criteria for research.
  • Existing criteria may lack specificity for observational studies and clinical trials.

Purpose of the Study:

  • To develop and validate new, highly specific classification criteria for antiphospholipid syndrome (APS).
  • To support the American College of Rheumatology (ACR) and EULAR in establishing updated APS diagnostic standards.

Main Methods:

  • An international, multidisciplinary initiative involving surveys, literature reviews, and modified Delphi techniques.
  • Criteria refinement through patient scenarios, consensus-based decision analysis, and validation using independent adjudicators.
  • Four-phase development process including generation, reduction, definition, and validation of criteria.

Main Results:

  • The 2023 ACR/EULAR APS criteria incorporate weighted clinical and laboratory domains.
  • A minimum score of 3 points from both clinical and laboratory domains is required for APS classification.
  • The new criteria demonstrated 99% specificity and 84% sensitivity in validation, outperforming the 2006 Sapporo criteria.

Conclusions:

  • Rigorous, internationally validated criteria for APS have been established.
  • The new criteria offer enhanced specificity, crucial for reliable APS research and trials.
  • These criteria represent a significant advancement in understanding and classifying antiphospholipid syndrome.